Diagnosis and treatment of intrahepatic cholestasis in chronic diseases of the liver
- 作者: Golovanova E.V.1, Petrakov A.V.1, Golovanova EV2, Petrakov AV2
-
隶属关系:
- Central Research Institute of Gastroenterology
- 期: 卷 83, 编号 2 (2011)
- 页面: 33-39
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.02.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30800
- ID: 30800
如何引用文章
全文:
详细
Aim. To improve diagnosis of intrahepatic cholestasis (IHC) basing on clinicobiochemical picture in chronic hepatic diseases (CHD) of different etiology with cholestasis and to develop a differential approach to treatment.
Material and methods. We examined 875 CHD patients with IHC with evaluation of the levels of the enzymes, biliary acids (BA), lipids, characteristics of hemostasis and phosphocalcium metabolism in blood. We also studied correlations and changes of the above parameters in IHC of different etiology. A comparative analysis of efficacy of mono- and combined treatment of CHD patients with IHC was made.
Results. We revealed correlations between the levels of the enzymes, bilirubin, lipids and BA concentration in blood serum; unfavourable prognostic value of aggravating cholemia; no correlations between content of serum BA, duration of IHC and intensity of skin itching (SI). We propose to establish "the degree of IHC severity" with 4 degrees of this severity. Characteristics of impairment of hemostasis and phosphocalcium metabolism in IHC of different etiology depending on the degree of IHC severity are presented. Efficacy and universality of combined treatment with ursodeoxicholic acid and ademetionin in moderate and severe IHC of different etiology are shown.
Conclusion. Introduction of the definition "the degree of IHC severity" allowed us to classify IHC by severity. This enables adequate assessment of the patient's condition, prognosis the risk of complications and their severity, a differential approach to treatment and, finally, improvement of the disease outcome prognosis.
Material and methods. We examined 875 CHD patients with IHC with evaluation of the levels of the enzymes, biliary acids (BA), lipids, characteristics of hemostasis and phosphocalcium metabolism in blood. We also studied correlations and changes of the above parameters in IHC of different etiology. A comparative analysis of efficacy of mono- and combined treatment of CHD patients with IHC was made.
Results. We revealed correlations between the levels of the enzymes, bilirubin, lipids and BA concentration in blood serum; unfavourable prognostic value of aggravating cholemia; no correlations between content of serum BA, duration of IHC and intensity of skin itching (SI). We propose to establish "the degree of IHC severity" with 4 degrees of this severity. Characteristics of impairment of hemostasis and phosphocalcium metabolism in IHC of different etiology depending on the degree of IHC severity are presented. Efficacy and universality of combined treatment with ursodeoxicholic acid and ademetionin in moderate and severe IHC of different etiology are shown.
Conclusion. Introduction of the definition "the degree of IHC severity" allowed us to classify IHC by severity. This enables adequate assessment of the patient's condition, prognosis the risk of complications and their severity, a differential approach to treatment and, finally, improvement of the disease outcome prognosis.
作者简介
Elena Golovanova
Email: golovanovaev@mail.ru
Aleksandr Petrakov
E Golovanova
Central Research Institute of GastroenterologyCentral Research Institute of Gastroenterology
A Petrakov
Central Research Institute of GastroenterologyCentral Research Institute of Gastroenterology
参考
- Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Пер. с англ. М.: ГЭОТАР-Медицина; 1999.
- Бабак О. Я. Синдром холестаза: что нужно знать каждому врачу. Укр. тер. журн. 2005; 3: 4-22.
- Подымова С. Д. Болезни печени. М.: Медицина; 1998. 246-264.
- Подымова С. Д. Внутрипеченочный холестаз: патогенез и лечение адеметионином. Клин. фармакол. и тер. 2006; 15 (2): 67-70.
- Лейшнер У. Аутоиммунные заболевания печени и перекрестный синдром. М.: Анахарсис; 2005.
- Флеркемайер В. Холестатические заболевания печени. Практическое руководство. Dr. Falk Farma GmbH; Фрайбург, 2006.
- Блюгер А. Ф., Новицкий И. Н. Практическая гепатология. Рига: Звайгзне; 1984.
- Bove K. E., Heubi J. E., Balistreri W. F., Setchell K. D. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr. Dev. Pathol. 2004; 7 (4): 315-334.
- Boyer J. L. Advancing the bile-ology of cholestasic liver disease. Hepatology 2001; 33 (suppl. 3): 758-759.
- Elferink R. Cholestasis. Gut 2003; 52 (suppl. II): 42-48.
- Ben-Ari Z., Panagou M., Patch D. et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J. Hepatol. 1997; 26: 554-559.
- Biagini M. R., Tozzi A., Marcucci R. et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. Wld J. Gastroenterol. 2006; 12 (10): 1607-1612.
补充文件
![](/img/style/loading.gif)